Education
About Us
Working with TipRanks
Follow Us
Puma Biotechnology (PBYI)
NASDAQ:PBYI
PBYI Stock Chart & Stats
$6.00
-$0.12(-3.21%)
At close: 4:00 PM EST
$6.00
-$0.12(-3.21%)
Day’s Range― - ―
52-Week Range$2.58 - $7.68
Previous CloseN/A
Volume522.58K
Average Volume (3M)562.57K
Market Cap
$299.15M
Enterprise Value$298.10M
Total Cash (Recent Filing)$97.50M
Total Debt (Recent Filing)$28.55M
Price to Earnings (P/E)5.6
Beta0.77
Next Earnings
Apr 30, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.26
Shares Outstanding50,876,488
10 Day Avg. Volume391,965
30 Day Avg. Volume562,573
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.28
Price to Sales (P/S)1.30
P/FCF Ratio7.13
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.31
Enterprise Value/Gross Profit1.75
Enterprise Value/Ebitda5.05
Forecast
1Y Price Target
$5.00Price Target Upside-16.67% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.4
Revenue Forecast (FY)$220.00M
Bulls Say, Bears Say
Bulls Say
Analyst ConfidencePuma's price target was adjusted upwards from $4.00 to $5.00, suggesting increased confidence in future performance.
EarningsPuma reported Q3 Nerlynx sales of $51.9MM, which was above consensus estimates of $47.5MM.
Financial OutlookThe company raised its FY 2025 revenue and net income guidance slightly, indicating a positive outlook.
Bears Say
Product ConfidenceThere is a lack of confidence in alisertib, and the recommendation remains at Hold.
Revenue ChallengesSignificant accelerations in product and royalty revenue are needed in Q4 to support the full year guidance.
Puma Biotechnology News
PBYI FAQ
What was Puma Biotechnology’s price range in the past 12 months?
Puma Biotechnology lowest stock price was $2.58 and its highest was $7.68 in the past 12 months.
What is Puma Biotechnology’s market cap?
Puma Biotechnology’s market cap is $299.15M.
When is Puma Biotechnology’s upcoming earnings report date?
Puma Biotechnology’s upcoming earnings report date is Apr 30, 2026 which is in 48 days.
How were Puma Biotechnology’s earnings last quarter?
Puma Biotechnology released its earnings results on Feb 26, 2026. The company reported $0.26 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.07.
Is Puma Biotechnology overvalued?
According to Wall Street analysts Puma Biotechnology’s price is currently Overvalued.
Does Puma Biotechnology pay dividends?
Puma Biotechnology does not currently pay dividends.
What is Puma Biotechnology’s EPS estimate?
Puma Biotechnology’s EPS estimate is -0.17.
How many shares outstanding does Puma Biotechnology have?
Puma Biotechnology has 50,876,488 shares outstanding.
What happened to Puma Biotechnology’s price movement after its last earnings report?
Puma Biotechnology reported an EPS of $0.26 in its last earnings report, beating expectations of $0.19. Following the earnings report the stock price went down -25%.
Which hedge fund is a major shareholder of Puma Biotechnology?
Currently, no hedge funds are holding shares in PBYI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Puma Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.00 (-16.67% Downside)
$5.00 (-16.67% Downside)
Hedge Fund Trend
Decreased
By 24.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.68%
12-Months-Change
Fundamentals
Return on Equity
39.69%
Trailing 12-Months
Asset Growth
-8.09%
Trailing 12-Months
Company Description
Puma Biotechnology
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
PBYI Company Deck
PBYI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented meaningful commercial momentum (QoQ and YoY revenue and volume growth), a large one-time royalty uplift, continued GAAP profitability in Q4 and faster-than-expected enrollment in a key Phase II breast cancer trial with interim data expected in Q2 2026. Offsetting this are soft new prescription trends, elevated gross-to-net deductions and higher near-term operating and R&D spend (with an anticipated Q1 2026 loss), plus inventory-related seasonality and modest cash depletion. On balance the company shows strong operational and clinical progress with manageable financial headwinds and near-term volatility.View all PBYI earnings summariesPBYI Stock 12 Month Forecast
Average Price Target
$5.00
▼(-16.67% Downside)
Technical Analysis
Heron Therapeutics
―
Voyager Therapeutics
―
Foghorn Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Ownership Overview
15.65% Insiders
15.55% Mutual Funds
7.33% Other Institutional Investors
48.29% Public Companies and
Individual Investors